24 studies found for:    triple negative breast cancer | Phase 3, 4
Show Display Options
Rank Status Study
1 Recruiting Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)
Conditions: Breast Tumor;   Breast Cancer;   Cancer of the Breast;   Estrogen Receptor- Negative Breast Cancer;   HER2- Negative Breast Cancer;   Progesterone Receptor- Negative Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer;   Triple-negative Breast Cancer;   Triple-negative Metastatic Breast Cancer;   Metastatic Breast Cancer
Interventions: Drug: nab-Paclitaxel 125 mg/m2 plus carboplatin AUC 2 in triple negative metastatic breast cancer (TNMBC) subjects;   Drug: Carboplatin AUC 2;   Drug: gemcitabine 1000 mg
2 Recruiting A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer
Condition: Triple Negative Breast Cancer
Interventions: Drug: Veliparib;   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Doxorubicin;   Drug: Cyclophosphamide;   Drug: Placebo
3 Recruiting Comparative Study on Two Post-operative Adjuvant Chemotherapy Regimens for Treating Triple-negative Breast Cancer
Condition: Breast Cancer
Interventions: Drug: 5-Fu/epirubicin/CTX following Docetaxel;   Drug: Docetaxel/capecitabine followed by XEC
4 Not yet recruiting A Phase III Trial of Carboplatin as Adjuvant Chemotherapy in Triple Negative Breast Cancer
Condition: Breast Cancer
Intervention: Drug: carboplatin
5 Active, not recruiting
Has Results
BEATRICE Study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer
Condition: Breast Cancer
Interventions: Drug: bevacizumab [Avastin];   Drug: Standard adjuvant chemotherapy
6 Active, not recruiting Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Paclitaxel in Triple Negative Breast Cancer (TNBC)
Condition: Breast Cancer
Interventions: Drug: Gemcitabine,cisplatin;   Drug: Gemcitabine, Paclitaxel
7 Recruiting Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer
Condition: Breast Cancer
Intervention:
8 Recruiting Efficacy of Capecitabine Metronomic Chemotherapy to Triple-negative Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Capecitabine (Xeloda);   Drug: Standard adjuvant chemotherapy
9 Not yet recruiting Adjuvant Endocrine Therapy for Estrogen Receptor-beta Positive Triple Negative Breast Cancer
Condition: Female Breast Cancer
Intervention: Drug: Toremifene; Anastrozole
10 Unknown  The Trial Comparing Dose-dense AC-T With PC as Adjuvant Therapy for TNBC
Condition: Breast Cancer
Intervention: Drug: epirubicin, cyclophosphamide, paclitaxel, carboplatin, G-CSF
11 Active, not recruiting A Study of Avastin With Taxane Therapy in Patients With Triple Negative Breast Cancer
Condition: Breast Cancer
Intervention: Drug: bevacizumab [Avastin]
12 Recruiting Neo Adjuvant Chemotherapy in Triple Negative Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Carboplatin and Paclitaxel;   Drug: Doxorubicin, cyclophosphamide;   Drug: Doxorubicin, cyclophosphamide, carboplatin, thiotepa, cyclophosphamide
13 Active, not recruiting Triple Negative Breast Cancer Trial
Condition: Breast Cancer
Interventions: Drug: Carboplatin;   Drug: Docetaxel
14 Active, not recruiting A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Doxorubicin;   Drug: Cyclophosphamide;   Drug: Ixabepilone (Ixempra);   Drug: Paclitaxel (Taxol)
15 Recruiting MRI and Mammography Before Surgery in Patients With Stage I-II Breast Cancer
Conditions: Estrogen Receptor-negative Breast Cancer;   HER2-negative Breast Cancer;   HER2-positive Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage II Breast Cancer;   Triple-negative Breast Cancer
Interventions: Procedure: Breast surgery;   Procedure: Magnetic resonance imaging;   Procedure: Mammography
16 Recruiting Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes
Conditions: HER2-Negative Breast Cancer;   Triple Negative Breast Cancer;   Breast Cancer;   Cancer of Breast;   Breast Tumors
Interventions: Drug: E7389 (Eribulin Mesylate);   Drug: Vinorelbine injection
17 Completed A Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer
Condition: Breast Cancer
Interventions: Drug: gemcitabine/carboplatin;   Drug: Iniparib
18 Not yet recruiting A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)
Conditions: Tubular Breast Cancer Stage II;   Tubular Breast Cancer Stage III;   Mucinous Breast Cancer Stage II;   Breast Cancer Female NOS;   Invasive Ductal Breast Cancer;   HER2 Positive Breast Cancer;   Inflammatory Breast Cancer
Interventions: Drug: non-pegylated liposomal doxorubicin;   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Epirubicin;   Drug: Cyclophosphamide;   Drug: Pertuzumab;   Drug: Trastuzumab;   Drug: Ferric carboxymaltose
19 Completed Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer
Conditions: Tubular Breast Cancer Stage II;   Mucinous Breast Cancer Stage II;   Breast Cancer Female NOS;   Invasive Ductal Breast Cancer;   Tubular Breast Cancer Stage III;   HER-2 Positive Breast Cancer;   Inflammatory Breast Cancer Stage IV;   Inflammatory Breast Cancer
Interventions: Drug: Carboplatin;   Drug: background treatment according to standards fpr triple negative and Her2pos breast cancer patients
20 Terminated Neoadjuvant Treatment of Docetaxel, Anthracycline and Cyclophosphamide (TAC) Versus Docetaxel and Cyclophosphamide (TC) in Triple-Negative or Her2 Positive Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Docetaxel, Anthracycline (Doxorubicin or Epirubicin), Cyclophosphamide;   Drug: Docetaxel, cyclophosphamide

   Previous Page Studies Shown (1-20) Next Page (21-24) Show next page of results    Last Page
Indicates status has not been verified in more than two years